Biosimilars for psoriasis: Preclinical analytical assessment to determine similarity

British Journal of Dermatology

Volumn 174, Issue 2, 2016, Pages 282-286

  Blauvelt, Andrew ^a   Cohen, A D ^b,c   Puig, L ^d   Vender, R ^e   Van Der Walt, J ^f   Wu, J J ^g  

^a OREGON MEDICAL RESEARCH CENTER   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Dermatrials Research   (Canada)

^f International Psoriasis Council   (United States)

^g KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; BIOSIMILAR AGENT; RECOMBINANT PROTEIN;

ANALYTIC METHOD; CLINICAL PRACTICE; HUMAN; PRECLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; REVIEW; BIOSYNTHESIS; CELL LINE; DRUG APPROVAL; GENETIC TRANSFECTION;

BIOSIMILAR PHARMACEUTICALS; CELL LINE; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; PSORIASIS; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84952837710     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14267     Document Type: Review

References (25)

1. Weise M, Bielsky MC, De Smet K, et al,. Biosimilars-why terminology matters. Nat Biotechnol 2011; 29: 690-3.
2. U.S. Department of Health and Human Services. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (last accessed 10 November 2015).
3. Strober BE, Armour K, Romiti R, et al,. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012; 66: 317-22.
4. O'Connor A, Rogge M,. Nonclinical development of a biosimilar: the current landscape. Bioanalysis 2013; 5: 537-44.
5. U.S. Department of Health and Human Services. Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf (last accessed 10 November 2015).
6. Lee JF, Litten JB, Grampp G,. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin 2012; 28: 1053-8.
7. Zuperl S, Pristovsek P, Menart V, et al,. Chemometric approach in quantification of structural identity/similarity of proteins in biopharmaceuticals. J Chem Inf Model 2007; 47: 737-43.
8. Schiestl M, Stangler T, Torella C, et al,. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-12.
9. Ebbers HC, Crow SA, Vulto AG, Schellekens H,. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012; 30: 1186-90.
10. Kálmán-Szekeres Z, Olajos M, Ganzler K,. Analytical aspects of biosimilarity issues of protein drugs. J Pharm Biomed Anal 2012; 69: 185-95.
11. Calvo B, Zuñiga L,. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development. Curr Med Chem 2012; 19: 4445-50.
12. U.S. Department of Health and Human Services. Food and Drug Administration. Reference product exclusivity for biological products filed under section 351(a) of the PHS act. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM407844.pdf (last accessed 10 November 2015).
13. Chirino AJ, Mire-Sluis A,. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22: 1383-91.
14. Schneider CK,. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72: 315-18.
15. European Medicines Agency. Refusal assessment report for Alpheon. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/000585/WC500070792.pdf (last accessed 10 November 2015).
16. Locatelli F, Roger S,. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21: v13-16.
17. Feagan BG, Choquette D, Ghosh S, et al,. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177-83.
18. U.S. Department of Health and Human Services. Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf (last accessed 10 November 2015).
19. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf (last accessed 10 November 2015).
20. Calvo B, Zuñiga L,. The US approach to biosimilars: the long-awaited FDA approval pathway. BioDrugs 2012; 26: 357-61.
21. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf (last accessed 10 November 2015).
22. European Medicines Agency. Guideline on similar biological medicinal products. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf (last accessed 10 November 2015).
23. Food and Drug Administration. ICH Q5E: comparability of biotechnological/biological products subject to changes in their manufacturing process. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/2004d-0118-gdl0001.pdf (last accessed 10 November 2015).
24. Ventola CL,. Biosimilars: part 1: proposed regulatory criteria for FDA approval. P T 2013; 38: 270-87.
25. Ventola CL,. Biosimilars: part 2: potential concerns and challenges for p&t committees. P T 2013; 38: 329-35.